No headlines found.
No press releases found.
No news found.
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on helping treat and manage cancer.
Tema Oncology ETF trades on the NASDAQ stock market under the symbol CANC.
As of September 11, 2026, CANC stock price declined to $41.53 with 28,519 million shares trading.
CANC has a beta of 0.67, meaning it tends to be less sensitive to market movements. CANC has a correlation of 0.12 to the broad based SPY ETF.
CANC has a market cap of $203.90 million. This is considered a Small Cap stock.
In the last 3 years, CANC traded as high as $47.00 and as low as $20.10.
CANC has outperformed the market in the last year with a return of +49.6%, while the SPY ETF gained +17.4%. In the last 3 month period, CANC beat the market returning +11.5%, while SPY returned +3.9%. However, in the most recent 2 weeks CANC has underperformed the stock market by returning -4.6%, while SPY returned -0.7%.
CANC support price is $41.06 and resistance is $42.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CANC shares will trade within this expected range on the day.
